Scott Blumberg Sells 33,512 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 33,512 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $25.03, for a total value of $838,805.36. Following the transaction, the chief financial officer owned 148,121 shares of the company’s stock, valued at approximately $3,707,468.63. This represents a 18.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Scott Blumberg also recently made the following trade(s):

• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total transaction of $24,750.00.

CeriBell Stock Down 2.3%

Shares of NASDAQ CBLL traded down $0.58 during trading on Thursday, reaching $24.31. The company had a trading volume of 262,277 shares, compared to its average volume of 469,652. The stock has a market cap of $933.02 million, a PE ratio of -13.81 and a beta of 0.81. The business’s 50-day moving average is $19.43 and its 200 day moving average is $19.19. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $25.33. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. As a group, equities analysts forecast that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CeriBell

Several large investors have recently made changes to their positions in CBLL. Strs Ohio bought a new stake in CeriBell in the 1st quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd lifted its position in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of CeriBell in the 3rd quarter worth about $33,000. CWM LLC raised its position in shares of CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares in the last quarter.

Analyst Upgrades and Downgrades

CBLL has been the topic of several research reports. BTIG Research raised their target price on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. Barclays upgraded CeriBell to a “neutral” rating in a research report on Tuesday. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Finally, Canaccord Genuity Group increased their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.40.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.